NervGen Pharma (NASDAQ: NGEN) files 2025 Form 40-F; 79.65M shares outstanding
Rhea-AI Filing Summary
NervGen Pharma Corp. files its Annual Report on Form 40-F for the fiscal year ended December 31, 2025. The filing lists 79,649,257 Common Shares outstanding, incorporates an Annual Information Form, audited consolidated financial statements for 2025 and 2024, MD&A, and certifications via listed exhibits. The registry signature is dated March 31, 2026.
Positive
- None.
Negative
- None.
Key Figures
Shares outstanding: 79,649,257 shares
Fiscal year end: December 31, 2025
Signature date: March 31, 2026
+2 more
5 metrics
Shares outstanding
79,649,257 shares
as of the close of the period ended December 31, 2025
Fiscal year end
December 31, 2025
reporting period for the Form 40-F
Signature date
March 31, 2026
date of authorized signature on the filing
Exhibit - financial statements
Exhibit 99.2
Consolidated Financial Statements for 2025 and 2024
Exhibit - AIF
Exhibit 99.1
Annual Information Form for year ended December 31, 2025
Key Terms
Form 40-F, Annual Information Form (AIF), MD&A, Inline XBRL, +1 more
5 terms
Form 40-F regulatory
"Annual Report on Form 40-F for the fiscal year ended December 31, 2025"
A Form 40-F is a standardized annual filing used by certain Canadian companies that trade in U.S. markets to give U.S. regulators and investors the same core financial statements and key disclosures they file in Canada. Think of it as a translated, formally packaged annual report that lets investors in a different marketplace compare a company’s results, governance and risks more easily, which reduces uncertainty and helps investment decisions.
Annual Information Form (AIF) regulatory
"Annual Information Form for the year ended December 31, 2025 (the “AIF”)"
An annual information form (AIF) is a comprehensive, regulatory disclosure document that gives a detailed snapshot of a company’s business, strategy, key assets, risks, capital structure and how it is run. Think of it as a company’s long-form dossier or owner’s manual that complements financial statements; investors use it to understand long-term risks, governance and the business model so they can make more informed decisions about value and future prospects.
MD&A financial
"Management’s Discussion and Analysis of Financial Condition and Results of Operations"
Management’s Discussion and Analysis (MD&A) is a section of a company’s financial filing where executives explain recent results, the reasons behind changes, risks faced, and expectations for the future in plain language alongside the numbers. Investors use it like an owner’s narrative to understand the story behind the raw financial data — what drove performance, potential pitfalls, and management’s plans — helping judge whether the company’s numbers are likely to improve or worsen.
Inline XBRL technical
"Inline XBRL Instance Document included as Exhibit 101.INS"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Audit committee financial expert regulatory
"Mr. Klompas is an “audit committee financial expert”"
A person on a company’s board who has deep knowledge of accounting, financial reporting and auditing, able to understand and question the books, controls and audit work like a trained mechanic inspecting an engine. Investors care because that expertise helps spot errors, weaknesses or misleading statements early, improving the likelihood that financial reports are accurate and reducing the risk of surprises that can hurt a company’s value.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
Which principal documents are incorporated by reference in NGEN's 40-F?
The filing incorporates an Annual Information Form (Exhibit 99.1), audited consolidated financial statements (Exhibit 99.2), MD&A (Exhibit 99.3), and related certifications and consents in Exhibits 99.4–99.8. These exhibits form the core annual disclosure package.
Who is listed as the audit committee financial expert in the filing?
The Board has designated Neil Klompas as an audit committee financial expert. The filing states that each audit committee member is independent and references the AIF for Mr. Klompas’ detailed biographical and financial-experience disclosure.
Does the 40-F indicate any differences between Nasdaq and Canadian governance practices?
Yes. The filing explains NervGen is a foreign private issuer and follows certain home-country practices in lieu of Nasdaq Rule 5600-series requirements, while complying with specified Nasdaq rules on voting rights, audit committee composition, and diversity disclosure.
What exhibits provide the financial statements and auditor consent?
Audited consolidated financial statements for 2025 and 2024 are filed as Exhibit 99.2, and the auditor consent from KPMG LLP is filed as Exhibit 99.4. These exhibits support the annual financial disclosures and attestations.